The Association for Cancer Immunotherapy CIMT is a member-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent non-profit organization. CIMT has its offices in Mainz, Germany, and has been financed by donations, congress fees, industry sponsorship and by the following public and foundation grants:
providing a member-based communications platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies.
educating health professionals through annual meetings, advanced education seminars and publications.
cooperating with partners in related consortia, regulatory agencies, journals, academic institutions and companies.
initiating and leading working groups that actively accelerate the development of cancer immunotherapies.
CIMT is governed by an international executive board of nine members who are elected for a three-year term by the members of the general assembly. The current board is appointed through 2020.
CIMT collaborates with major international organizations like the Cancer Immunotherapy Consortium of the Cancer Research Institute (CRI-CIC) and the American Association for Cancer Research (AACR). CIMT is a FOCIS members society and maintains a partnership with the Japanese Association for Cancer Immunotherapy (JACI). Furthermore, CIMT cooperates with the journal Cancer Immunology Immunotherapy (CII).
CIMT is also a dissemination platform for GAPVAC, the EU funded Glioma Actively Personalized Vaccine Consortium.
“Forschungszentrum Immunologie” (FZI) aims at supporting all immunological research activities at the university hospital of Mainz and the Johannes Gutenberg University. FZI promotes the exchange between scientists from different fields. Its goal is to increase the visibility of research carried out by FZI partners, and additionally coordinates multi-disciplinary research activities. CIMT and FZI agreed on a statement of cooperation to foster international visibility and provide structured education for their partners. FZI has been an official co-organizer of the CIMT Annual Meeting since 2010.
Cancer Research Institute: Cancer Immunotherapy Consortium
Since 2008, CIMT and the Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) have joined forces in different projects. Our CIMT Immunoguiding Program (CIP) has partnered with CIC to set new standards and harmonize protocols for immunoassays used in cancer immunotherapy studies. Furthermore, the CIMT Regulatory Research Group is in dialogue with CIC to address the challenges posed by regulatory rules for clinical development by the new era of individualized medicine.
American Association for Cancer Research (AACR)
The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.
GAPVAC (Glioma Actively Personalized Vaccine Consortium) is a EU-funded project focusing on the development of a fully and actively personalized vaccination approach, in which patients will be treated based on specific characteristics of their individual disease. GAPVAC is divided into a section for pre-clinical/ translational development and a subsequent clinical phase I trial to assess safety, feasibility and immunogenicity. CIMT acts as a dissemination platform for the GAPVAC project by communicating the results of the GAPVAC consortium to the scientific and clinical community.
Cancer Immunology, Immunotherapy (CII)
The international journal “Cancer Immunology, Immunotherapy” (CII) is the official partner journal of CIMT. The partnership includes the presentation of scientific content, such as meeting reports, symposium papers and abstracts.
In 2011, CIMT was granted society membership of the Federation of Clinical Immunology Societies (FOCIS). CIMT and all CIMT members can take full advantage of being a FOCIS Members Society including professional development resources and discounted registration fees at FOCIS events. CIMT has also been given the opportunity to organize Members Society Symposia as part of the annual meeting of the Federation of Clinical Immunology Societies.
Society for Immunotherapy of Cancer (SITC)
CIMT shares SITC’s mission of advancing the science, development and application of immunotherapy through communication and leadership. SITC and CIMT are developing future collaborations, especially in the fields of education, biomarker development and regulatory aspects of innovative cancer immunotherapy.
Japanese Association for Cancer Immunology (JACI)
In 2013, CIMT and the Japanese Association for Cancer Immunology, JACI, entered into a partnership to share information, support each other and join forces to reach common goals. CIMT and JACI consult each other on scientific meetings and symposia and provide assistance in the regulation of cancer immunotherapy trials.
Click on the cover to download the PDF version of our 2016 Annual Report.
Cron A, Gouttefangeas C, Frelinger J, Lin L, Singh SK, Britten CM, Welters MJ, van der Burg SH, West M, Chan C. Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol. 2013;9(7):e1003130. doi: 10.1371/journal.pcbi.1003130. Epub 2013 Jul 11
McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S. A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A. 2013 Aug;83(8):728-38. doi: 10.1002/cyto.a.22319. Epub 2013 Jun 20
Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJM, O’Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff THM, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. Immunity 2012;37:1-2
Singh SK, Meyering M, Ramwadhdoebe TH, Stynenbosch LF, Redeker A, Kuppen PJ, Melief CJ, Welters MJ, van der Burg SH. The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunol Immunother. 2012;61:1953-63
Welters MJ, Gouttefangeas C, Ramwadhdoebe TH, Letsch A, Ottensmeier CH, Britten CM, van der Burg SH. Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother 2012;61:967-978 Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, M.J.P. Welters, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother November 9 2012.
Singh SK, Tummers B, Schumacher TN, Gomez R, Franken KL, Verdegaal EM, Laske K, Gouttefangeas C, Ottensmeier C, Welters MJ, Britten CM, van der Burg SH. The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunol Immunother. September 2012.
Sjoerd H. van der Burg, Michael Kalos, Cecile Gouttefangeas, Sylvia Janetzki, Christian Ottensmeier, Marij J.P. Welters, Pedro Romero, Cedrik M. Britten, Axel Hoos. Harmonization of immune biomarker assays for clinical studies. Science Translational Medicine 3, 108ps44 (2011).
Axel Hoos, Cedrik M Britten, Christoph Huber, Jill O’Donnell-Tormey. A methodological framework to enhance the clinical success of cancer immunotherapy. Nature Biotechnology 29, 867-870 (2011). (Open Access publication). Published online 13 October 2011.
C. M. Britten, S. Janetzki, S. H. van der Burg, C. Huber, M. Kalos, H. I. Levitsky, H. T. Maecker, C. J. M. Melief, J. O’Donnell-Tormey, K. Odunsi, L. J. Old, G. Pawelec, B. O. Roep, P. Romero, A. Hoos, and M. M. Davis. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother. 2011 January; 60(1): 15–22.
Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O’Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother. 2011 Jan;60(1):15-22.
Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother. 2010 Oct;59(10):1489-501..
Mander A, Gouttefangeas C, Ottensmeier C, Welters MJ, Low L, van der Burg SH, Britten CM. Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunol Immunother. 2010 Apr;59(4):619-27. Epub 2010 Jan 6.
Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM.. MIATA: Minimal Information About T cell Assays. Immunity, Volume 31, Issue 4, 527‐528, 16 October 2009 .
Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.Cancer Immunol Immunother. 2008 Mar;57(3):289-302. Epub 2007 Aug 25.
C. M. Britten, S. Janetzki, S. H. van der Burg, C. Gouttefangeas and A. Hoos. Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunology, Immunotherapy (26 August 2007) [OPEN ACCESS].
Kathleen Hobohm, Torsten Seppmann, Cedrik M. Britten, Holger Hoff. A methodological framework to enhance the clinical success of cancer immunotherapy.Cancer Immunology, Immunotherapy DOI: 10.1007 s00262-011-1131-2
Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen K-J, Khleif SN, Kreiter S, Nielsen M, Rammensee H-G, Sahin U, Hinz T, Kalinke U (2013): The regulatory landscape for actively personalized cancer immunotherapies, Nature Biotechnology 31 (10), 880-882. doi 10.1038/nbt.2708.
Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, Sahin U, Singh-Jasuja H, Türeci Ö15, Kalinke U. The European Regulatory Environment of RNA-Based Vaccines. Methods in Molecular Biology. 2017. Volume 1499. pp 203-222
Diken, M.; Chu, K.K., Brodsky, A. N. Translating Science into Survivial: Report on the Third International Cancer Immunotherapy Conference. Cancer Immunology Research; 6(1) January 2018.
Kranz LM, Birtel M, Hilscher L, Grunwitz C, Petschenka J, Vascotto F, Vormehr M, Voss RH, Kreiter S, Diken M. CIMT 2016: Mechanisms of efficacy in cancer research – Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy. May 10-12, 2016, Mainz, Germany. Human Vaccines & Immunotherapeutics. November 2016
Miller M, Jahndel V, Kutscher S, Mahr A, Rae R, Kloke BP.
The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11-13, 2015. Cancer Immunology Immunotherapy. October 2016.
Kranz L., Birtel M., Krienke C., Grunwitz C., Petschenka J., Reuter K., van de Roemer N., Vascotto F., Vormehr M., Kreiter S., Diken M. CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy. Human Vaccines & Immunotherapeutics. July 2015.
Diken M., Boegel S., Grunwitz C., Kranz L., Reuter K., van de Roemer N., Vascotto F., Vormehr M.; Kreiter S. CIMT 2014: Next waves in cancer immunotherapy - report on the 12th annual meeting of the Association for Cancer Immunotherapy. Human Vaccines & Immunotherapeutics. January 2015.
Kloke BP, Mahr A, Jabulowsky RA, Kutscher S, Rae R, Britten CM. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014. Cancer Immunology, Immunotherapy. December 2014.
Kloke BP, Rae R, Mahr A, Burkhardt UE, Kvistborg P, Britten CM.Towards the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013. Cancer Immunol Immunother. 2013 Nov 5.
Diken M., Attig S., Grunwitz C., Kranz L., Simon P., van de Roemer N. , Vascotto F., Kreiter S. Advancing targeted therapies—report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14–16 2013, Mainz, Germany. Human Vaccines & Immunotherapeutics 9:9, 2025–2032; September 2013.
Kloke BP, Kutscher S, Rae R, Kvistborg P, Britten CM, Hadrup SR. Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012. Cancer Immunol Immunotherapy. 2013 May; 62(5):975-81. doi: 10.1007/s00262-012-1386-2. Epub 2013 Jan 9.
Hobohm K, Seppmann T, Britten CM, Hoff H. Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25-27, 2011, Mainz, Germany. Cancer Immunol Immunother. 2012 Jan;61(1):137-43. doi: 10.1007/s00262-011-1131-2. Epub 2011 Nov 3.
Singh SK, Laske K, Gouttefangeas C, Britten CM, Welters MJ. CIMT 2010: report on the eighth annual meeting of the Association for Cancer Immunotherapy, May 26-28, 2010, Mainz, Germany. Cancer Immunol Immunother. 2011 Mar;60(3):443-50. Epub 2010 Nov 23. No abstract available
Diken M, Widenmeyer M, Gouttefangeas C, Welters MJ, Britten CM. CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer. June 3-5, Mainz, Germany. Cancer Immunol Immunother. 2010 Sep;59(9):1417-23. Epub 2009 Sep 22. No abstract available.
Welters MJ, van Montfoort N, Khan S, Meyer RG, Britten CM. Report on the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), May 15 and 16, 2008 in Mainz, Germany. Cancer Immunol Immunother. 2009 May;58(5):777-87. Epub 2008 Nov 4. No abstract available
Welters MJ, Gouttefangeas C, Attig S, Koch S, Britten CM. Report on the Fifth Annual Meeting of the Association for Immunotherapy of Cancer (CIMT) April 12-14, 2007 in Würzburg, Germany. Cancer Immunol Immunother. 2008 Jan;57(1):135-42. Epub 2007 Oct 6. No abstract available.
Gouttefangeas C, Britten CM, Badalians ED, Pawelec G. CIMT meets strategies for immune therapy. Report and abstracts of the 4th International Meeting of the Association for Immunotherapy of Cancer, Mainz, Germany, 4-5 May 2006 . Cancer Immunol Immunother. 2007 Mar;56(3):397-427. Epub 2006 Aug 11. No abstract available.
Britten CM, Gouttefangeas C, Kreiter S. Cancer immunotherapy 2005: Mainz, Germany, 12-13 May 2005. Cancer Immunol Immunother. 2006 Apr;55(4):475-80. Epub 2005 Sep 29
Britten CM, Mueller L, Knights A, Pawelec G. Cancer Immunotherapy 2004: Mainz, Germany, 6-7 may 2004. Cancer Immunol Immunother. 2004 Dec;53(12):1153-8. No abstract available.